Osman ÖZÜDOĞRU, Çiğdem GÜNGÖRMEZ, Mehmet UYUKLU

COVID-19 ENFEKSİYONUNDA İMMÜN PLAZMA TEDAVİSİ: SİİRT DENEYİMİ

Amaç: Dünyada hızla yayılan COVID-19 salgını Türkiye’de de insanları önemli derecede etkilemektedir. Tedaviye yönelik çeşitli ilaç-metodlar denenmekte olup bu uygulamalardan biride immun plazma transfüzyonudur. Gereç ve Yöntem: Bu çalışmada Siirt Eğitim ve Araştırma Hastanesi'nde COVID-19 teşhisli tedavi gören 23 hastaya uygulanan 400cc immün plazma tedavisi, etkisini göstermek için retrospektif olarak değerlendirilmiştir. Bulgular: İmmün plazma tedavisinden önce hastaların mekanik ventilasyon kullanımı %47,82 iken, 3 gün sonra bu gereksinimin %30,43 e düştüğü gözlemlenmiştir. İmmün plazma tedavisi alan 23 hastadan 9'u tedavilerini tamamlayarak iyileşti. Sonuç: Her ne kadar hastalar üzerinde uygulanan immün plazma tedavisi, hastaların iyileşmesine katkıda bulunsa da kesin olarak etki ettiğine dair kanıtlar yetersizdir. Bu nedenle immün plazma transfüzyon etkinliğini belgelemek için daha fazla sayıda COVID-19 hastası ile gözlem yapılması gerekmektedir.

Immune plasma therapy in COVID-19 infection: the experience of Siirt

Objective: COVID-19 pandemic which is rapidly spreading in the world affects people in Turkey significantly. Various drug-methods for treatment are being tried and one of these applications is immune plasma transfusion. Materials and Methods: In this study, 400cc immune plasma treatment was evaluated retrospectively to show the effect of treatment applied to 23 patients with COVID-19 diagnosis in Siirt Training and Research Hospital. Results: It was observed that the use of mechanical ventilation was 47.82% before the immune plasma treatment, while this need decreased to 30.43% after 3 days. Nine out of 23 patients who received immune plasma therapy recovered by completing their treatment. Conclusion: Although the immune plasma applied on patients contributes to the recovery of patients, the evidence is yet insufficient. Therefore, more COVID-19 patients need to be observed to document the efficiency of immune plasma transfusion therapy.

PDF

___

1. Lu H, Stratton CW, Tang Y W. Outbreak of pneumonia of unknown etiology in Wuhan China: The mystery and the miracle. J MedVirol. 2020; 92(4):401 2.
2. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) and coronavirus disease 2019 (COVID 19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;105924.
3. Chan JFW, Yuan S, Kok KH, Wang KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person toperson transmission: A study of a family cluster. Lancet. 2020;395:514–23.
4. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall R, Manson JJ, et al. COVID 19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 28;395(10229):1033 4.
5. Mc Gonagle D, Sharif K, O’Regan A, Bridgewood C. The Role of Cytokines including Interleukin 6 in COVID 19 induced Pneumonia and Macrophage Activation Syndrome Like Disease. Autoimmun Rev. 2020;19(6):102537.
6. Ripoll JG, Helmond NV, Senefeld JW, Wiggins CC, Klassen SA, Baker SE, et al. Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID 19. Clin Microbiol Newsl. 2021;43(4):23 32.
7. Nomoto H, Kutsuna S, Okuma K, Kuramitsu M, Tezuka K, Ikebe E, et al. No SARS CoV 2 RNA detected in the convalescent plasma of COVID 19 patients with different disease severity. J Infect Chemother 2021:27(4):653 5.
8. Alsharidah S, Ayed M, Ameen RM, Alhuraish F, Rouheldeen NA, Alshammari FR, et al. COVID 19 convalescent plasma treatment of moderate and severe cases of SARS CoV 2 infection: A multicenter interventional study. Int J Infect Dis. 2021;103:439 46.
9. Kan Hizmetleri Genel Mudurlugu, Kan ve Kan Urunleri Dairesi Baskanligi[Internet]. [Erisim Tarihi: 01 Ocak2021] Erisim adresi: https: //shgmkanhizmetleridb.saglik.gov.tr/TR 76536/covid 19 immun konvalesan plazma tedarik ve klinikkullanim rehberi guncellendi.html
10. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507–13.
11. World Health Organization, [Internet]. [Erisim Tarihi: 11Subat 2020] Erisim adresi: https: //www.who.int/director general/speeches/detail/whodirector general s remarks at the media briefing on 2019 ncov on 11 february 2020.
12. Guan WJ, Liang Wh, Zhao Y, Liang Hr, Chen Zs, Li Ym, et al. Comorbidity and its impact on 1590 patients with COVID 19 in China: a nationwide analysis. Eur Respir J. 2020;55:2000547.
13. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID 19. Lancet Infect Dis. 2020;20(4):398–400.
14. Erkurt MA, Sarici A, Berber I, Kuku I, Kaya E, Ozgul M. Life saving effect of convalescent plasma treatment in covid 19 disease: Clinical trial from eastern Anatolia. Transfus Apher Sci. 2020;59:102867.
15. Altuntas F, Ata N, Yigenoglu TN, Bascı S, Dal MS, Korkmaz S, et al. Convalescent plasma therapy in patients with COVID 19. Transfus Apher Sci. 2021;60: 102955.
16. Duan K, Liu B, Zhang H, Yu, T, Qu J, Zhou M, et al. Effectiveness of convalescent plasma therapy in severe COVID 19 patients. Proc Natl Acad Sci. 2020;117(17):9490–6.